(Q44522454)

English

Toward standard HER2 testing of endometrial serous carcinoma: 4-year experience at a large academic center and recommendations for clinical practice

scientific article published on 14 June 2013

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

3 December 2017

Toward standard HER2 testing of endometrial serous carcinoma: 4-year experience at a large academic center and recommendations for clinical practice (English)

1 reference

Europe PubMed Central

3 December 2017

serous carcinoma

1 reference

based on heuristic

inferred from title

author name string

Natalia Buza

1

1 reference

Europe PubMed Central

3 December 2017

Diana P English

2

1 reference

Europe PubMed Central

3 December 2017

Alessandro D Santin

3

1 reference

Europe PubMed Central

3 December 2017

Pei Hui

4

1 reference

Europe PubMed Central

3 December 2017

publication date

14 June 2013

1 reference

Europe PubMed Central

3 December 2017

Modern Pathology

1 reference

Europe PubMed Central

3 December 2017

26

1 reference

Europe PubMed Central

3 December 2017

12

1 reference

Europe PubMed Central

3 December 2017

1605-1612

1 reference

Europe PubMed Central

3 December 2017

https://scigraph.springernature.com/pub.10.1038/modpathol.2013.113

0 references

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2013.113

21 January 2018

HER2 expression in gastric and gastroesophageal junction adenocarcinoma in a US population: clinicopathologic analysis with proposed approach to HER2 assessment.

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2013.113

21 January 2018

HER2 amplification, overexpression and score criteria in esophageal adenocarcinoma.

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2013.113

21 January 2018

HER2 testing in gastric cancer

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2013.113

21 January 2018

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2013.113

21 January 2018

Determination of HER2/neu status in uterine serous papillary carcinoma: Comparative analysis of immunohistochemistry and fluorescence in situ hybridization.

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2013.113

21 January 2018

HER-2/neu receptor gene status in endometrial carcinomas: a tissue microarray study.

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2013.113

21 January 2018

HER-2/neu overexpression in uterine papillary serous cancers and its possible therapeutic implications.

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2013.113

21 January 2018

Clinicopathological and prognostic impact of human epidermal growth factor receptor type 2 (HER2) and hormone receptor expression in uterine papillary serous carcinoma.

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2013.113

21 January 2018

An exploratory analysis of HER-2 amplification and overexpression in advanced endometrial carcinoma: a Gynecologic Oncology Group study.

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2013.113

21 January 2018

Racial differences in the overexpression of epidermal growth factor type II receptor (HER2/neu): a major prognostic indicator in uterine serous papillary cancer

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2013.113

21 January 2018

Development of targeted therapy in uterine serous carcinoma, a biologically aggressive variant of endometrial cancer

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2013.113

21 January 2018

Expression of EGFR, HER-2/neu, P53, and PCNA in endometrioid, serous papillary, and clear cell endometrial adenocarcinomas

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2013.113

21 January 2018

Serous carcinoma of the uterus-determination of HER-2/neu status using immunohistochemistry, chromogenic in situ hybridization, and quantitative polymerase chain reaction techniques: its significance and clinical correlation

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2013.113

21 January 2018

Rare uterine cancers

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2013.113

21 January 2018

Trastuzumab treatment in patients with advanced or recurrent endometrial carcinoma overexpressing HER2/neu

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2013.113

21 January 2018

Phase II trial of trastuzumab in women with advanced or recurrent, HER2-positive endometrial carcinoma: a Gynecologic Oncology Group study

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2013.113

21 January 2018

Letter to the Editor referring to the manuscript entitled: "Phase II trial of trastuzumab in women with advanced or recurrent HER-positive endometrial carcinoma: a Gynecologic Oncology Group study" recently reported by Fleming et al., (Gynecol Oncol

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2013.113

21 January 2018

Personalized therapy in endometrial cancer: challenges and opportunities

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2013.113

21 January 2018

Analysis of HER-2/neu amplification in endometrial carcinoma by chromogenic in situ hybridization. Correlation with fluorescence in situ hybridization, HER-2/neu, p53 and Ki-67 protein expression, and outcome

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2013.113

21 January 2018

The relationship of cerb B 2 expression with estrogen receptor and progesterone receptor and prognostic parameters in endometrial carcinomas

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2013.113

21 January 2018

Does breast tumor heterogeneity necessitate further immunohistochemical staining on surgical specimens?

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2013.113

21 January 2018

Clinical significance of intratumoral HER2 heterogeneity in gastric cancer

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2013.113

21 January 2018

Her-2/neu overexpression and amplification in uterine papillary serous carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2013.113

7 January 2021

based on heuristic

inferred from DOI database lookup

HER-2/neu amplification and overexpression in endometrial carcinoma.

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2013.113

7 January 2021

based on heuristic

inferred from DOI database lookup

HER-2 is an independent prognostic factor in endometrial cancer: association with outcome in a large cohort of surgically staged patients

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2013.113

7 January 2021

based on heuristic

inferred from DOI database lookup

Uterine papillary serous adenocarcinoma. A 10-case study of p53 and c-erbB-2 expression and DNA content

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2013.113

7 January 2021

based on heuristic

inferred from DOI database lookup

HER-2/neu overexpression and amplification in uterine serous papillary carcinoma: comparative analysis of immunohistochemistry, real-time reverse transcription-polymerase chain reaction, and fluorescence in situ hybridization

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2013.113

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical significance of Her-2/neu overexpression in uterine serous carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2013.113

7 January 2021

based on heuristic

inferred from DOI database lookup

Uterine serous carcinoma. A morphologically diverse neoplasm with unifying clinicopathologic features

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2013.113

7 January 2021

based on heuristic

inferred from DOI database lookup

Uterine papillary serous and clear cell carcinomas predict for poorer survival compared to grade 3 endometrioid corpus cancers

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2013.113

7 January 2021

based on heuristic

inferred from DOI database lookup

Use of trastuzumab in the treatment of metastatic endometrial cancer

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2013.113

7 January 2021

based on heuristic

inferred from DOI database lookup

Intratumoral heterogeneity of HER2/neu in breast cancer--a rare event

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2013.113

7 January 2021

based on heuristic

inferred from DOI database lookup

Human epidermal growth factor receptor 2 testing in gastric carcinoma: issues related to heterogeneity in biopsies and resections

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2013.113

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1038/MODPATHOL.2013.113

1 reference

Europe PubMed Central

3 December 2017

Dimensions Publication ID

0 references

release_aci4q6cmbjgr5jqc6obvwbsxxe

1 reference

https://api.fatcat.wiki/v0/release/aci4q6cmbjgr5jqc6obvwbsxxe

24 November 2022

based on heuristic

mapped directly with Wikidata item

1 reference

Europe PubMed Central

3 December 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44522454&oldid=2026855806"